Motoya Kitamura, previously managing partner of Japanese secondaries investor AB Value Capital Partners, has joined HQ Capital as a managing director.
Based in Hong Kong and Tokyo, Kitamura will join the firm’s Asia investment team, with a special focus on Japan. Prior to joining AB Value – formerly Ant Capital Partners – in 2018, he spent more...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.